The pathway to commercialization for nanomedicine

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 1, Issue 1, 2005, Pages 47-51

  Flynn, Ted ^a   Wei, Chiming ^b  

^a Potomac Investment Capital LLC   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Business; Commercialization; Development; Nanomedicine; Nanotechnology

Indexed keywords

COMMERCIALIZATION; DEVELOPMENT; MULTIDISCIPLINARY APPROACH; NANOMEDICINE;

CHEMICAL INDUSTRY; COMMERCE; CONTROLLED DRUG DELIVERY; INVESTMENTS; MARKETING; MEDICINE;

NANOTECHNOLOGY;

NANOPARTICLE;

ARTICLE; BIOTECHNOLOGY; COMMERCIAL PHENOMENA; EVALUATION; FOOD AND DRUG ADMINISTRATION; INVESTMENT; MARKETING; MEDICINE; NANOMEDICINE; NANOTECHNOLOGY; PARTICLE SIZE;

COMMERCE; DEVICE APPROVAL; INDUSTRY; INVESTMENTS; NANOMEDICINE; TECHNOLOGY TRANSFER; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33645022352     PISSN: 15499634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nano.2004.11.010     Document Type: Article

References (10)

1. Roco M. Report on nanotechnology (2003), National Science Foundation, Arlington (VA)
2. Espicom Research. White paper. Chichester (UK): Epsicom Consulting; 2004. Available at: www.espicom.com
3. Centers for Medicare and Medicaid Services, Health and Human Services. Annual report on prescription expenditures Washington (DC): US Printing office; 2001.
4. Biotechnology Industry Organization (BIO) 2003 annual report. USA Today, 7 June 2004:1.
5. Biotechnology Industry Organization annual report (2003)
6. Bioworld annual report on life sciences (2003), Ernst and Young, Bethesda (Md)
7. National Institutes of Health. Road map for the future of nanomedicine (2004), National Institutes of Health, Bethesda (Md)
8. Washington (DC): Food and Drug Administration, Health and Human Services; 2002.
9. Stormer H. Capital report on nanotechnology (2002), Lux Research, New York
10. Biologic and environmental nanotechnology (2004)